79 results
Page 4 of 4
6-K
EX-99.1
a77twvc0ahjfodm
5 Jan 21
InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
7:30am
6-K
EX-99.3
1nqmcsx sw
29 Oct 20
Current report (foreign)
7:05am
6-K
EX-99.1
gqbqo2js yakdql3
29 Oct 20
Current report (foreign)
7:05am
6-K
EX-99.1
cxoko1wr2pmxi hi
17 Sep 20
InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer
7:31am
6-K
EX-99.1
uaru6r sflr
14 Sep 20
InflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced Pneumonia
7:36am
6-K
EX-99.1
cadm5
6 Aug 20
InflaRx to Present at Upcoming Virtual Investor Events
7:35am
6-K
EX-99.2
q1ou3vky
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.1
9inmafhk8
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.3
dx6mfwbd7b j2i
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.1
7tr0ly75
21 Jul 20
InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia
7:35am
424B5
12qr4 97jw
20 Jul 20
Prospectus supplement for primary offering
9:21am
F-3
6h7hcuwn9r5h49
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
EX-99.1
zfmh2kyun6m0
17 Jun 20
InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19
7:30am
6-K
EX-99.3
vdgti2m8eik7jcmj
21 May 20
Current report (foreign)
8:09am
6-K
EX-99.1
m2pinkc1gcumo09a8 fi
21 May 20
Current report (foreign)
8:09am
6-K
EX-99.2
ir5 bfca3685
21 May 20
Current report (foreign)
8:09am
6-K
EX-99.1
gfyingrfqqfvkrsl
29 Apr 20
InflaRx Reports Full Year 2019 Financial & Operating Results
8:00am
6-K
EX-99.1
cmd8pmdlp3c31
31 Mar 20
Current report (foreign)
9:29pm